304
Views
1
CrossRef citations to date
0
Altmetric
Clinical Research

Predictors of FabAV use in copperhead envenomation

, , , , , , & show all
Pages 609-614 | Received 15 Jun 2021, Accepted 09 Dec 2021, Published online: 06 Jan 2022

References

  • Ruha AM, Pizon AF. Native (US) venomous snakes and lizards. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS., editor. Goldfrank's Toxicologic Emergencies. 11th ed. McGraw Hill; 2019. p. 1617–1626.
  • Gold BS, Barish RA, Dart RC. North American snake envenomation: diagnosis, treatment, and management. Emerg Med Clin North Am. 2004;22(2):423–443, ix.
  • Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol. 2020;58(12):1360–1541.
  • Greene SC, Folt J, Wyatt K, et al. Epidemiology of fatal snakebites in the United States 1989-2018. Am J Emerg Med. 2021;45:309–316.
  • Chippaux J-P. Incidence and mortality due to snakebite in the Americas. PLoS Negl Trop Dis. 2017;11(6):e0005662.
  • Langley RL, Morrow WE. Deaths resulting from animal attacks in the United States. Wilderness Environ Med. 1997;8(1):8–16.2.3.CO;2]
  • Walker JP, Morrison RL. Current management of copperhead snakebite. J Am Coll Surg. 2011;212(4):470–474. discussion 474–475.
  • BTG International Inc. CroFab® [prescribing Information]. 2018.
  • Boyer LV. On 1000-Fold pharmaceutical price markups and why drugs cost more in the United States than in Mexico. Am J Med. 2015;128(12):1265–1267.
  • Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030–2036.
  • Gerardo CJ, Vissoci JRN, Scott Evans C, et al. Does this patient have a severe snake envenomation?: the rational clinical examination systematic review. JAMA Surg. 2019;154(4):346–354.
  • Gerardo CJ, Quackenbush E, Lewis B, et al. The efficacy of crotalidae polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: a randomized, double-blind, placebo-controlled, clinical trial. Ann Emerg Med. 2017;70(2):233–244.e3.
  • Gerardo CJ, Vissoci JRN, Brown MWJ, et al. Coagulation parameters in copperhead compared to other crotalinae envenomation: secondary analysis of the F(ab')2 versus Fab antivenom trial. Clin Toxicol. 2017;55(2):109–114.
  • Correa JA, Fallon SC, Cruz AT, et al. Management of pediatric snake bites: are we doing too much? J Pediatr Surg. 2014;49(6):1009–1015.
  • Gale SC, Peters JA, Allen L, et al. FabAV antivenin use after copperhead snakebite: clinically indicated or knee-jerk reaction? J Venom Anim Toxins Incl Trop Dis. 2016;22:2.
  • Lawrence WT, Giannopoulos A, Hansen A. Pit viper bites: rational management in locales in which copperheads and cottonmouths predominate. Ann Plast Surg. 1996;36(3):276–285.
  • Seifert SA, Boyer LV, Benson BE, et al. AAPCC database characterization of native U.S. venomous snake exposures, 2001–2005. Clin Toxicol. 2009;47(4):327–335.
  • Whitley RE. Conservative treatment of copperhead snakebites without antivenin. J Trauma. 1996;41(2):219–221.
  • Caravati EM. Copperhead bites and crotalidae polyvalent immune fab (ovine): routine use requires evidence of improved outcomes. Ann Emerg Med. 2004;43(2):207–208.
  • Cannon R, Ruha A-M, Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune fab antivenom. Ann Emerg Med. 2008;51(4):407–411.
  • Khobrani M, Huckleberry Y, Boesen KJ, et al. Incidence of allergic reactions to crotalidae polyvalent immune fab. Clin Toxicol. 2019;57(3):164–167.
  • Kleinschmidt K, Ruha A-M, Campleman S, et al. Acute adverse events associated with the administration of crotalidae polyvalent immune fab antivenom within the North American snakebite registry. Clin Toxicol. 2018;56(11):1115–1120.
  • Schaeffer TH, Khatri V, Reifler LM, et al. Incidence of immediate hypersensitivity reaction and serum sickness following administration of crotalidae polyvalent immune fab antivenom: a meta-analysis. Acad Emerg Med. 2012;19(2):121–131.
  • Mullins ME, Gerardo CJ, Bush SP, et al. Adverse events in the efficacy of crotalidae polyvalent immune fab antivenom vs placebo in recovery from copperhead snakebite trial. South Med J. 2018;111(12):716–720.
  • Anderson VE, Gerardo CJ, Rapp-Olsson M, et al. Early administration of fab antivenom resulted in faster limb recovery in copperhead snake envenomation patients. Clin Toxicol. 2019;57(1):25–30.
  • Freiermuth CE, Lavonas EJ, Anderson VE, et al. Antivenom treatment is associated with fewer patients using opioids after copperhead envenomation. West J Emerg Med. 2019;20(3):497–505.
  • Lavonas EJ, Gerardo CJ. Prospective study of recovery from copperhead snake envenomation: an observational study. BMC Emerg Med. 2015;15:9.
  • Scharman EJ, Noffsinger VD. Copperhead snakebites: clinical severity of local effects. Ann Emerg Med. 2001;38(1):55–61.
  • Lavonas EJ, Ruha A-M, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2.
  • Kanaan NC, Ray J, Stewart M, et al. Wilderness medical society practice guidelines for the treatment of pitviper envenomations in the United States and Canada. Wilderness Environ Med. 2015;26(4):472–487.
  • Miller A, Parsh B. Caring for patients with venomous crotalinae snakebites. Nursing. 2020;50(2):56–60.
  • Gerardo CJ, Evans CS, Kuchibhatla M, et al. Time to antivenom administration is not associated with total antivenom dose administered in a copperhead-predominant snakebite population. Acad Emerg Med. 2015;22(3):308–314.
  • Dart RC, Seifert SA, Carroll L, et al. Affinity-purified, mixed monospecific crotalid antivenom ovine fab for the treatment of crotalid venom poisoning. Ann Emerg Med. 1997;30(1):33–39.
  • Morandi N, Williams J. Snakebite injuries: contributing factors and intentionality of exposure. Wilderness Environ Med. 1997;8(3):152–155.2.3.CO;2]
  • Ruha A-M, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North American snakebite registry. J Med Toxicol. 2017;13(4):309–320.
  • Schulte J, Domanski K, Smith EA, et al. Childhood victims of snakebites. Pediatrics. 2016;138(5):e20160491–2013.
  • Irion VH, Barnes J, Montgomery BEE, et al. Presentation and management of venomous snakebites: Should all patients be transferred to a tertiary referral hospital? J Surg Orthop Adv. 2016;25(2):69–73.
  • Edgerton MT, Koepplinger ME. Management of snakebites in the upper extremity. J Hand Surg Am. 2019;44(2):137–142.
  • Thorson A, Lavonas EJ, Rouse AM, et al. Copperhead envenomations in the carolinas. J Toxicol Clin Toxicol. 2003;41(1):29–35.
  • O'Neil ME, Mack KA, Gilchrist J, et al. Snakebite injuries treated in United States emergency departments, 2001-2004. Wilderness Environ Med. 2007;18(4):281–287.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.